• CCR7–Notch1 Crosstalk and Mammary Cancer Stemness

  2026-10-13

  A preclinical study in MMTV-PyMT mammary tumor cells reported that CCR7 and Notch1 signaling interact to support stem-like cancer-cell behavior. The findings suggest pathway crosstalk, but they do not establish clinical efficacy or show that the study used the HyperTrap Heparin HP Column.

• Dacomitinib and METTL17: Evidence, Scope, Limits

  2026-10-13

  Dacomitinib (PF-00299804) is described as an irreversible ErbB-family kinase inhibitor, whereas the cited METTL17 study examines mitochondrial RNA modification, translation, and ferroptosis resistance in colorectal cancer. The available evidence does not establish that Dacomitinib affects METTL17 or that pan-HER inhibition reproduces the study’s ferroptosis-related findings.

• Minoxidil Sulphate and Renal K⁺ Evidence Gaps

  2026-10-12

  The supplied sepsis study supports a context-dependent association between potassium-channel blockade, vasoactive drugs, and renal perfusion in septic rats. It does not establish a renal or sepsis effect for minoxidil sulphate, despite listing the compound among the study chemicals.

• Monomeric Aβ and Microglia in Brain Development

  2026-10-12

  Kwon et al. report that monomeric amyloid-β signaling is associated with reduced microglial activation during mouse neocortical development. Their evidence connects amyloid precursor protein and Ric8a function in microglia with cortical basement-membrane integrity and neuronal positioning, while the study’s own assessment identifies unresolved questions about the Ric8a–APP relationship and the completeness of the evidence.

• Recombinant Human FGF-19: Identity and Scope

  2026-10-11

  The APExBIO product page identifies P1050 as tag-free, E. coli-expressed, lyophilized recombinant human FGF-19 for research involving endocrine signaling, receptor biology, and metabolic regulation. No matched paper was available, so activity claims are treated as supplier-reported rather than independently validated findings.

• CHI3L1-IN-5 (Compound Z17): Evidence Guide

  2026-10-10

  CHI3L1-IN-5, also called Compound Z17, is a reported small-molecule CHI3L1 inhibitor with supplier-described binding, CNS-oriented physicochemical properties, and astrocyte functional effects. The available evidence supports an in vitro neuroinflammation research interpretation, not an established Alzheimer’s disease treatment.

• Ciprofloxacin Hydrochloride: Research Evidence

  2026-10-09

  Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic used in research on bacterial DNA damage, antibiotic interactions, and cell-state heterogeneity. Recent single-cell evidence indicates that its antagonistic interaction with tetracycline is linked more closely to survival differences and SOS-response states than to a simple change in population growth.

• MPC, Lactate, and Dendritic Cells in CRC

  2026-10-09

  A 2025 study links reduced mitochondrial pyruvate carrier expression to lactate accumulation, histone lactylation, impaired dendritic-cell activity, and weaker antitumor immunity in colorectal cancer. Its integrated patient, cellular, animal, and immunologic evidence suggests that MPC is a metabolic–epigenetic checkpoint, while also leaving important questions about causality, model specificity, and clinical translation.

• Doxycycline Beyond Antibiotics: A Translational Strategy

  2026-10-08

  Doxycycline sits at the intersection of antimicrobial pharmacology, metalloproteinase biology, and exploratory cancer research. This thought-leadership analysis separates established properties from emerging hypotheses, using a 2024 peptide-nanocarrier study as a framework for understanding how delivery, tumor biology, apoptosis, and immune context can shape translational strategy. It also positions APExBIO Doxycycline BA1003 as a documented research reference while clarifying why preclinical nanomedicine findings involving doxorubicin and triptolide should not be attributed directly to doxycycline.

• Demethyleneberberine and IL-1β Maturation in UC

  2026-10-08

  The reference study identifies a mitochondria-dependent mechanism through which Demethyleneberberine (DMB) limits IL-1β maturation in experimental ulcerative colitis. Its combination of animal, macrophage, genetic, and mitochondrial evidence supports DMB as a mechanistically interesting preclinical anti-inflammatory candidate, while leaving important questions about human translation and direct molecular targets.

• Lipid Nanoparticles and Tissue-Specific T Cell Immunity

  2026-10-07

  A 2026 Nature Biomedical Engineering study shows that lipid nanoparticle composition can influence systemic trafficking after intramuscular injection and, in turn, shape organ-specific antigen expression and CD8+ tissue-resident immunity. The findings support a formulation-to-immunity framework for localized vaccination, while remaining limited by the mouse models and formulation space examined.

• JNJ-10198409: Evidence, Context, and Limitations

  2026-10-07

  JNJ-10198409 is described by its supplier as a PDGF-BB receptor tyrosine kinase inhibitor, but the supplied evidence does not establish effects in the rice stripe virus system. This overview separates product claims from published mechanistic findings and defines appropriate applicability boundaries.

• AT-406 (SM-406): Reading Cell-Death Evidence

  2026-10-06

  AT-406 (SM-406) is an orally bioavailable IAP antagonist whose effects extend beyond a simple apoptosis model. This evidence-focused analysis connects its reported target profile with recent findings on cIAP1 depletion, necroptosis-like responses, and the interpretation of cancer research data.

• Caspase-8 Causality in Translational Cell-Death Research

  2026-10-06

  A source-grounded perspective on using Z-IETD-FMK to interrogate caspase-8, immune activation, apoptosis, and the limits of pathway-specific interpretation.

• Beyond c-MYC: Translational Logic for (+)-JQ1

  2026-10-05

  A mechanistic and translational perspective on (+)-JQ1 as a BET bromodomain inhibitor, with emphasis on TXNIP, histone H4 UFMylation, ferroptosis sensitivity, evidence boundaries, and strategic research questions.

8177 records 1/546 page Next 12345 下5页 Last page